Article Type
Changed
Fri, 01/18/2019 - 14:29
Display Headline
VIDEO: Search for genetic risk factors may improve vincristine therapy

Discovery of a genetic variation that may boost the risk of peripheral neuropathy for some cancer patients on vincristine therapy could lead to better treatment regimens for those patients.

Investigators uncovered the genetic variation in a study that analyzed DNA samples from 321 children with acute lymphoblastic leukemia who received standard vincristine therapy while participating in two prospective clinical trials (JAMA 2015 Feb. 24 [doi:10.1001/jama.2015.0894]).

William E. Evans, Pharm.D., and Kristine R. Crews, Pharm.D., both of St. Jude Children’s Research Hospital, Memphis, Tenn., discussed what spurred the search for genetic risk factors and what’s next for researchers looking to cut the chance of side effects associated with vincristine treatment in a video interview.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel

trudd@frontlinemedcom.com

References

Author and Disclosure Information

Publications
Topics
Legacy Keywords
vincristine, cancer, peripheral neuropathy, acute lymphoblastic leukemia
Author and Disclosure Information

Author and Disclosure Information

Discovery of a genetic variation that may boost the risk of peripheral neuropathy for some cancer patients on vincristine therapy could lead to better treatment regimens for those patients.

Investigators uncovered the genetic variation in a study that analyzed DNA samples from 321 children with acute lymphoblastic leukemia who received standard vincristine therapy while participating in two prospective clinical trials (JAMA 2015 Feb. 24 [doi:10.1001/jama.2015.0894]).

William E. Evans, Pharm.D., and Kristine R. Crews, Pharm.D., both of St. Jude Children’s Research Hospital, Memphis, Tenn., discussed what spurred the search for genetic risk factors and what’s next for researchers looking to cut the chance of side effects associated with vincristine treatment in a video interview.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel

trudd@frontlinemedcom.com

Discovery of a genetic variation that may boost the risk of peripheral neuropathy for some cancer patients on vincristine therapy could lead to better treatment regimens for those patients.

Investigators uncovered the genetic variation in a study that analyzed DNA samples from 321 children with acute lymphoblastic leukemia who received standard vincristine therapy while participating in two prospective clinical trials (JAMA 2015 Feb. 24 [doi:10.1001/jama.2015.0894]).

William E. Evans, Pharm.D., and Kristine R. Crews, Pharm.D., both of St. Jude Children’s Research Hospital, Memphis, Tenn., discussed what spurred the search for genetic risk factors and what’s next for researchers looking to cut the chance of side effects associated with vincristine treatment in a video interview.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel

trudd@frontlinemedcom.com

References

References

Publications
Publications
Topics
Article Type
Display Headline
VIDEO: Search for genetic risk factors may improve vincristine therapy
Display Headline
VIDEO: Search for genetic risk factors may improve vincristine therapy
Legacy Keywords
vincristine, cancer, peripheral neuropathy, acute lymphoblastic leukemia
Legacy Keywords
vincristine, cancer, peripheral neuropathy, acute lymphoblastic leukemia
Article Source

FROM JAMA

PURLs Copyright

Inside the Article